Branded Legacy, Inc. (OTC: BLEG), a company known for its focus on health and wellness solutions, has taken a significant step towards expanding its intranasal drug delivery portfolio by signing a non-binding Letter of Intent to acquire Bio-Legacy Evaluative Group. This acquisition, valued at $1.5 million in Preferred D stock, would see Branded Legacy taking over 100% of Bio-Legacy's equity, assets, and intellectual property. This strategic move is poised to position Branded Legacy in the rapidly growing markets for addiction treatments and vaccine accessibility, sectors that are increasingly vital in today's health-conscious world.
The significance of this acquisition lies in Bio-Legacy's patented naloxone device, which addresses critical challenges in cost and dosing within a market projected to surpass $1.16 billion by 2032. The device represents a breakthrough in intranasal drug delivery technology, offering a more efficient and accessible solution for emergency treatment of opioid overdoses. Following the completion of the acquisition, Amin Janmohamed, the current CEO of Bio-Legacy, is set to assume the roles of CEO and Chairman of Branded Legacy, bringing his expertise and vision to the forefront of the company's expansion efforts.
Manufacturing prototyping for the naloxone device is targeted for the third quarter of 2025, with the aim of achieving market readiness by the first quarter of 2027. This timeline underscores the company's commitment to not only advancing its technological capabilities but also to making a tangible impact on public health challenges. The acquisition of Bio-Legacy Evaluative Group by Branded Legacy, Inc. marks a pivotal moment in the company's growth strategy, highlighting its dedication to innovation and its potential to significantly influence the health and wellness industry.
